- Home
- IPSC vs EVAX Comparison
IPSC vs EVAX Comparison
Compare IPSC & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPSC | EVAX |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.8M | 42.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IPSC | EVAX |
|---|---|---|
| Price | $0.58 | $6.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.00 | ★ $12.33 |
| AVG Volume (30 Days) | ★ 934.8K | 100.4K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,337,000.00 | $7,650,000.00 |
| Revenue This Year | $1,590.09 | $128.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4122.69 | 132.17 |
| 52 Week Low | $0.34 | $1.20 |
| 52 Week High | $1.38 | $12.15 |
Technical Indicators
Market Signals| Indicator | IPSC | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 50.34 |
| Support Level | $0.50 | $6.15 |
| Resistance Level | $0.62 | $6.70 |
| Average True Range (ATR) | 0.04 | 0.51 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 64.59 | 41.88 |
Price Performance
Historical ComparisonAbout IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.